Successful treatment of recalcitrant cutaneous sarcoidosis with fumaric acid esters

BMC Dermatology

Volumn 2, Issue , 2002, Pages

  Nowack, Ute ^a   Gambichler, Thilo ^a   Hanefeld, Christoph ^a   Kastner, Ulrike ^a   Altmeyer, Peter ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SALT; CHLOROQUINE; CORTICOSTEROID; FUMADERM; FUMADERM INITIAL; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; MAGNESIUM SALT; TOPICAL AGENT; ZINC DERIVATIVE; ETHYL FUMARATE; FUMARIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; EYE DISEASE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; GRANULOMA; HUMAN; LUNG SARCOIDOSIS; LYMPHADENOPATHY; LYMPHOCYTOPENIA; PSORIASIS; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; CASE REPORT;

ADULT; FEMALE; FUMARATES; HUMANS; SARCOIDOSIS; SKIN DISEASES;

EID: 2942586808     PISSN: 14715945     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-5945-2-15     Document Type: Article

References (17)

1. English JC, Patel PJ and Greer KE Sarcoidosis. J Am Acad Dermatol 2001, 44:725-43
2. Müller-Quernheim J Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998, 12:716-38
3. Wilson N and King C Cutaneous sarcoidosis. Postgrad Med J 1998, 74:649-52
4. Kataria Y and Holter J Immunology of sarcoidosis. Clin Chest Med 1997, 18:719-39
5. Selroos O Treatment of sarcoidosis. Sarcoidosis 1994, 11:80-3
6. Altmeyer P, Hartwig R and Matthes U Das Wirkungs- und Sicherheitsprofil von Fumarsäureestern in der oralen Langzeittherapie bei schwerer therapieresistenter Psoriasis vulgaris. Hautarzt 1996, 47:190-6
7. Mrowietz U, Christophers E and Altmeyer P Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use. Br J Dermatol 1999, 141:424-9
8. Milburn HJ, Poulter LW, Dilmec A, Cochrane GM and Kemeny DM Corticosteroids restore the balance between locally produced Th1 and Th2 cytokines and immunoglobulin isotypes to normal in sarcoid lung. Clin Exp Immunol 1997, 108:105-13
9. Zhu K and Mrowietz U Inhibition of dentritic cell differentiation by fumaric acid esters. J Invest Dermatol 2001, 116:203-8
10. Höxtermann S, Nüchel C and Altmeyer P Fumaric acid esters suppress peripheral CD4- and CD8-positve lymphocytes in psoriasis. Dermatology 1998, 196:223-230
11. Asadullah A, Schmid H and Friedrich M Influence of monomethylfumarate on monocytic cytokine formation - explanation for adverse and therapeutic effects in psoriasis? Arch Dermatol Res 1997, 289:623-30
12. Okamoto H Epidermal changes in cutaneous lesions of sarcoidosis. Am J Dermatopathol 1999, 21:229-33
13. Schulze-Dirks A and Petzoldt D Disseminated granuloma annulare - successful therapy with fumaric acid esters. Hautarzt 2001, 52:228-30
14. Kreuter A, Gambichler T, Altmeyer P and Brockmeyer NH Treatment of disseminated granuloma annulare with fumaric acid esters. BMC Dermatol 2002, 2:5
15. Harrison P and Shuster S Granuloma annulare and sarcoidosis. Br J Dermatol 1979, 100:231
16. Dümmler U, Rinke M, Sabel R and Gollnick H Sarkoidose mit kutaner Dissemination: Zwei Fälle unter Fumarsäuretherapie. Allergologie 1998, 8:387 [Abstract]
17. Thio HB, van der Schroeff JG, Nugteren-Huying WM and Vermeer BJ Long-term systemic therapy with dimethylfumarate and monoethylfumarate (Fumaderm®) in psoriasis. J Eur Acad Dermatol Venereol 1995, 4:35-40